Show 40 moreShow less
Cohort A: Duration of Neoadjuvant and Adjuvant Therapy by Type
Cohort A: Proportion of Patients by Year of ET Initiation
Cohort A: Duration of ET by Type
Cohort A: Duration of Other CDK4/6i Treatment by Type
Cohort A: Proportion of Patients by Type of Concomitant Medication Received
Cohort B and Subcohort B1: Proportion of Patients Who Switch to an Alternative CDK4/6i
Cohort B and Subcohort B1: Proportion of Patients Who Receive Concomitant Systemic and Local Oncology Therapies
Cohort B and Subcohort B1: Proportion of Patients Who Receive Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation
Cohort B and Subcohort B1: Duration of Subsequent Systemic and Local Oncology Therapies Administered After Ribociclib Initiation, by Type of Therapy
Cohort B and Subcohort B1: Time Between Discontinuation of Ribociclib and Start of Subsequent Systemic and Local Oncology Therapies, by Type of Therapy
Cohort B and Subcohort B1: Initial Dose of Ribociclib
Cohort B and Subcohort B1: Proportion of Patients Who Undergo Ribociclib Dose Reduction
Cohort B and Subcohort B1: Time to First Ribociclib Dose Reduction
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Reduction
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Dose Reduction
Cohort B and Subcohort B1: Proportion of Patients Who Experience Ribociclib Dose Interruption
Cohort B and Subcohort B1: Time to First Ribociclib Dose Interruption
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Dose Interruption
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Dose Interruption
Cohort B and Subcohort B1: Proportion of Patients Who Discontinue Ribociclib Treatment
Cohort B and Subcohort B1: Time-to-Discontinuation (TTD) of Ribociclib Treatment
Cohort B and Subcohort B1: Proportion of Patients by Reason for Ribociclib Discontinuation
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Interruptions per Patient Prior to Ribociclib Discontinuation
Cohort B and Subcohort B1: Number of Prior Ribociclib Dose Reductions per Patient Prior to Ribociclib Discontinuation
Cohort B and Subcohort B1: Persistence of Ribociclib Treatment
Cohort B and Subcohort B1: Number of Clinical Visits and/or Laboratory Assessments for Ribociclib Monitoring
Cohort B and Subcohort B1: Cumulative Exposure to Ribociclib
Subcohort B1: Incidence of Adverse Events (AEs) of Interest
Subcohort B1: Proportion of Patients Requiring Changes to the Ribociclib Regimen Following AE Occurrence
Subcohort B1: Proportion of Patients by the Sequalae of AEs
Cohort B and Subcohort B1: Proportion of Patients Undergoing Drug-drug Interaction (DDI) Assessment Upon Ribociclib Initiation
Cohort B and Subcohort B1: Proportion of Patients With Actual DDIs
Cohort B and Subcohort B1: Number of DDIs per Patient
Cohort A: Proportion of Patients With Potential DDIs
Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs
Cohort B and Subcohort B1: Proportion of Patients With Potential DDIs Who Experience AEs
Cohort B and Subcohort B1: Proportion of Patients by Clinical Monitoring Practices Before and After DDI Occurrence
Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by Demographics and Clinical Characteristics
Cohort B and Subcohort B1: Among Patients With Clinically Consequential DDIs, Number of Patients by BC Treatment Prior to Ribociclib
Cohort B and Subcohort B1: Frequency of Ribociclib Treatment Modifications Related to DDIs